Skip to main content
. 2024 Jan 11;42(11):1265–1277. doi: 10.1200/JCO.23.01796

TABLE A6.

Multivariable Associations Comparing Individuals Within IGHG-Defined Risk Groups Based Upon Cumulative Doses of Anthracyclines and Chest Radiation Adjusting for rs2229774

Variable HR (95% CI) P
Race
 White Ref
 Non-White 1.44 (0.93 to 2.24) .11
Sex
 Male Ref
 Female 0.81 (0.57 to 1.14) .23
Age at diagnosis, years
 0-4 Ref
 5-9 1.37 (0.85 to 2.21) .20
 10-14 1.08 (0.66 to 1.76) .77
 15-19 1.07 (0.61 to 1.87) .81
No. of cardiovascular risk factors
 None Ref
 1 0.98 (0.64 to 1.49) .92
 ≥2 1.30 (0.82 to 2.04) .27
IGHG risk group
 Low Ref
 Moderate, without anthracycline 0.71 (0.08 to 6.41) .76
 Moderate, with anthracycline 1.70 (0.69 to 4.19) .25
 High, without anthracycline 6.71 (2.35 to 19.16) <.001
 High, with anthracycline 3.95 (1.67 to 9.34) .002
IGHG low-risk group
 GLS normal/NT-proBNP normal Ref
 GLS abnormal/NT-proBNP normal 1.15 (0.29 to 4.48) .84
 GLS normal/NT-proBNP abnormal 0.00 (0.00 to 3.34) .27
 GLS abnormal/NT-proBNP abnormal 0.00 (0.00 to 18.6) .62
 GLS normal/NT-proBNP unavailable 2.07 (0.68 to 6.27) .20
 GLS abnormal/NT-proBNP unavailable 1.78 (0.36 to 8.77) .48
IGHG moderate-/high-risk group, without anthracycline
 GLS normal/NT-proBNP normal Ref
 GLS abnormal/NT-proBNP normal 0.72 (0.21 to 2.45) .60
 GLS normal/NT-proBNP abnormal 0.40 (0.08 to 1.91) .25
 GLS abnormal/NT-proBNP abnormal 0.88 (0.30 to 2.58) .82
 GLS normal/NT-proBNP unavailable 1.83 (0.22 to 15.14) .57
 GLS abnormal/NT-proBNP unavailable 0.00 (0.00 to 1.79) .99
IGHG moderate-/high-risk group, with anthracycline
 GLS normal/NT-proBNP normal Ref
 GLS abnormal/NT-proBNP normal 0.98 (0.50 to 1.92) .96
 GLS normal/NT-proBNP abnormal 2.15 (1.15 to 4.01) .016
 GLS abnormal/NT-proBNP abnormal 4.29 (2.33 to 7.89) <.001
 GLS normal/NT-proBNP unavailable 2.66 (1.34 to 5.29) .005
 GLS abnormal/NT-proBNP unavailable 4.24 (2.09 to 8.60) <.001

NOTE. Adjusted for age at baseline and rs2229774.

Abbreviations: GLS, global longitudinal strain; HR, hazard ratio; IGHG, International Guideline Harmonization Group; NT-proBNP, N-terminal-pro-B-type natriuretic peptide; Ref, reference.